3D Bioprinting stands at the forefront of biomedical innovation, offering transformative potential for creating functional tissues, thereby advancing regenerative medicine and in vitro testing methods. However, challenges such as reproducibility, scalability, and bioink standardisation remain. The PSIS workshop, with 56 experts from 17 countries, highlighted the importance of standardisation in overcoming key challenges to reproducibility, quality, and safety. Participants focused on standardisation needs for bioinks, biomaterials, printing equipment, and quality and safety assessments, paving the way for impactful advancements. This collaborative approach underscores the need for updated regulatory frameworks to safely integrate 3D Bioprinting into healthcare, enhancing personalised medicine and fostering groundbreaking biomedical applications. In particular, the need for standards regarding 3D Bioprinting process and materials (bioinks) emerged, together with the demand of adapting standards for cells and tissues from nearby sectors, as well as for quality and safety assessment.
MADDALON Ambra;
PIERGIOVANNI Monica;
ZIMMER Sophie;
URBAN LOPEZ Patricia;
DALIER Claire;
ARMAS Federica;
OGBONNA Jennifer;
BARRERO Josefa;
COLPO Pascal;
KOURTI Naouma;
2026-03-11
Publications Office of the European Union
JRC145664
978-92-68-37567-9 (online),
1831-9424 (online),
EUR 40642,
OP KJ-01-26-069-EN-N (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC145664,
10.2760/7650391 (online),
